Chong Kun Dang runs new global drug for treatment of dyslipidemia
As new clinical trial results of dyslipidemia treatment were recently revealed in the U.S., ‘CKD-519’ being developed by Chong Kun Dang has raised expectations.
CKD-519, a new dyslipidemia drug with a new mechanism that reduces low density lipoprotein(LDL) cholesterol and neutral fat that are ha...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
